World Lung 2021 – front-line competition lines up behind Keytruda

When it comes to combining immuno-oncology drugs with chemotherapy in front-line lung cancer doctors are spoilt for choice. Yesterday the IASLC World Conference on Lung Cancer featured two more me-too anti-PD-(L)1/chemo combos, from Chinese groups that could soon challenge the US dominance of Merck & Co’s Keytruda.